Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Hosted on MSN7h
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
Are Investors Being Too Paranoid About Pfizer Stock?
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
Pfizer Inc. stock underperforms Tuesday when compared to competitors
Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.
Pfizer's Options Frenzy: What You Need to Know
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Jefferies raises Pfizer stock price target to $34, maintains Buy
Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...
https//insights.som.yale.edu4d
What Investors Are Missing about Pfizer and Merck
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Pfizer: Challenges Loom Amid Overvaluation
Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...
Better High-Yield Dividend Stock: Pfizer vs. Merck
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, ...